Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09IMS
|
|||
| Former ID |
DAP001078
|
|||
| Drug Name |
Mequitazine
|
|||
| Synonyms |
Butix; Instotal; Kitazemin; Mequitazina; Mequitazinum; Metaplexan; Mircol; Primalan; Quitadrill; Vigigan; Virginan; Zesulan; Italfarmaco brand of mequitazine; Mequitazina [Spanish]; Mequitazine hydrochloride; Pierre Fabre brand of mequitazine; LM 209; Kitazemin (TN); LM-209; Mequitazina [INN-Spanish]; Mequitazinum [INN-Latin]; Mequitazine (JP15/INN); Mequitazine [INN:BAN:DCF:JAN]; Mequitazine tartrate, (R-(R*,R*))-isomer; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; 10-(3-Quinuclidinylmethyl)phenothiazine; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-(9CI); 3-Methylquinuclidinyl-10-phenothiazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allergic rhinitis [ICD-11: CA08.0] | Approved | [1] | |
| Respiratory disease [ICD-11: CB40] | Phase 2 | [2] | ||
| Therapeutic Class |
Antihistamines
|
|||
| Company |
Pierre Fabre SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H22N2S
|
|||
| Canonical SMILES |
C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
|
|||
| InChI |
1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
|
|||
| InChIKey |
HOKDBMAJZXIPGC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 29216-28-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
453325, 583144, 7366094, 7848387, 8141047, 8152552, 10320045, 10517343, 11406959, 14850608, 16617285, 26665232, 29223177, 46505779, 48416221, 50006661, 53787706, 56320321, 57322124, 57962172, 78247115, 81093314, 85209426, 87244027, 92714662, 103267575, 103815311, 104305332, 104972177, 117404379, 124799813, 124894252, 125347181, 126623962, 126655271, 126669303, 128089981, 131309176, 134338335, 134997033, 137267684, 140724147, 142143428, 144207197, 160964405, 163121882, 164761785, 164814342, 170005238, 170465794
|
|||
| ChEBI ID |
CHEBI:31821
|
|||
| SuperDrug ATC ID |
R06AD07
|
|||
| SuperDrug CAS ID |
cas=029216282
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drug information of Mequitazine, 2008. eduDrugs. | |||
| REF 2 | ClinicalTrials.gov (NCT01951222) Bronchodilator Properties and Safety in Asthma. U.S. National Institutes of Health. | |||
| REF 3 | Efficiency of mequitazine in the treatment of allergic rhinitis and chronic urticaria in children. A bibliographic systematic review. Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.